The European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK's Menveo vaccine ...

GSK’s fully liquid presentation of its meningococcal vaccine Menveo has been approved by the European Commission (EC) to ...

Until now, Menveo was approved as a lyophilised/liquid formulation. Year to date, shares of GSK have lost 7.4% compared with the industry’s decline of 7.9%. Image Source: Zacks Investment Research ...

GSK (GSK) announced that the European Commission, EC, has approved a single-vial, fully liquid presentation of Menveo to help protect against invasive meningococcal disease, IMD, caused by ...

In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...

European Commission approves GSK’s fully liquid Menveo meningococcal vaccine: London, UK Friday, November 29, 2024, 11:00 Hrs [IST] GSK plc announced that the European Commissio ...

The European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK's Menveo vaccine (MenACWY), designed to protect against invasive meningococcal disease (IMD ...

GSK plc GSK announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of its meningococcal vaccine, Menveo (MenACWY) for active immunization in children ...

London: GSK plc has announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of ...